GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Arecor Therapeutics PLC (LSE:AREC) » Definitions » 3-Year FCF Growth Rate

Arecor Therapeutics (LSE:AREC) 3-Year FCF Growth Rate : -41.60% (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is Arecor Therapeutics 3-Year FCF Growth Rate?

Arecor Therapeutics's Free Cash Flow per Share for the six months ended in Dec. 2023 was £-0.05.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was -41.60% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was -64.60% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.

During the past 7 years, the highest 3-Year average Free Cash Flow per Share Growth Rate of Arecor Therapeutics was -41.60% per year. The lowest was -137.10% per year. And the median was -60.40% per year.


Competitive Comparison of Arecor Therapeutics's 3-Year FCF Growth Rate

For the Biotechnology subindustry, Arecor Therapeutics's 3-Year FCF Growth Rate, along with its competitors' market caps and 3-Year FCF Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Arecor Therapeutics's 3-Year FCF Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arecor Therapeutics's 3-Year FCF Growth Rate distribution charts can be found below:

* The bar in red indicates where Arecor Therapeutics's 3-Year FCF Growth Rate falls into.



Arecor Therapeutics 3-Year FCF Growth Rate Calculation

This is the 3-year average growth rate of Free Cash Flow per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average Free Cash Flow per Share growth rate.


Arecor Therapeutics  (LSE:AREC) 3-Year FCF Growth Rate Explanation

Free Cash Flow per Share is the amount of Free Cash Flow per outstanding share of the company's stock. Free Cash Flow is considered one of the most important parameters to measure a company's earnings power by value investors because it is not subject to estimates of Depreciation, Depletion and Amortization (DDA). However, when we look at the Free Cash Flow, we should look from a long term perspective, because any year's Free Cash Flow can be drastically affected by the spending on Property, Plant, & Equipment (PPE) of the business in that year. Over the long term, Free Cash Flow should give pretty good picture on the real earnings power of the company. It's used in the calculation of Forward Rate of Return (Yacktman) %.


Arecor Therapeutics 3-Year FCF Growth Rate Related Terms

Thank you for viewing the detailed overview of Arecor Therapeutics's 3-Year FCF Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Arecor Therapeutics (LSE:AREC) Business Description

Traded in Other Exchanges
Address
Chesterford Research Park, Little Chesterford, Saffron Walden, GBR, CB10 1XL
Arecor Therapeutics PLC is a focused biopharmaceutical company. The company is transforming patient care by bringing innovative medicines to market through the enhancement of existing therapeutic products. By applying an innovative proprietary formulation technology platform, Aresta. It is developing a portfolio of proprietary products in diabetes and other indications and working with pharmaceutical and biotechnology companies to deliver enhanced reformulations of their therapies. Geographically, it operates in the UK, Switzerland, the Rest of Europe, the USA, India, and the Rest of the World, out of which the majority is from the UK.